Table 2.
Demographic, clinical and neuropsychological data of patient subgroups (means, standard deviations and group differences)
| Features/measures | AA/AT (n = 11) | TT (n = 4) | Group differences (P-values)a |
|---|---|---|---|
| Male/female | 6/5 | 3/1 | 0.571 |
| Handedness (right/left/both) | 10/0/1 | 3/0/1 | — |
| Age (years) | 66.3 (10.3) | 65.3 (13.1) | 0.869 |
| Beck Depression Inventory-II score | 9.8 (7.5) | 11.0 (1.4) | 0.628 |
| Montreal Cognitive Assessment score | 25.6 (2.5) | 25.8 (2.6) | 0.901 |
| MDS-UPDRS-III scoreb | 24.8 (11.5) | 28.8 (6.9) | 0.753 |
| Levodopa equivalent daily dose (mg/day) | 338.9 (278.7) | 508.8 (185.2) | 0.224 |
| Picture ordering task | |||
| Fbp during encoding (Hz)c | 8.8 (0.6) | 7.9 (0.7) | 0.374 |
| Fbp during the delay (Hz) | 9.3 (0.5) | 9.4 (1.0) | 0.901 |
| Fbp power during encoding (μV2) | 0.99 (0.20) | 2.28 (1.15) | 0.287 |
| Fbp power during the delay (μV2) | 1.57 (0.43) | 2.96 (1.41) | 0.354 |
| Test of Attentional Performance (TAP) working memory | |||
| Number of correct responses (one-tailed) | 11.6 (3.0) | 9.0 (2.9) | 0.083 |
| Median reaction time (ms, one-tailed) | 726.7 (178.0) | 939.3 (205.2) | 0.038* |
a
Group differences, P-values of two-sample t-tests with bootstrap (500 times); asterisks, significant group differences (P < 0.05).
b
MDS-UPDRS, Movement Disorder Society-sponsored revision of Unified Parkinson’s Disease Rating Scale.
c
Fbp, baseline peak frequency.